Klotho Neurosciences ( (KLTO) ) has issued an announcement.
Klotho Neurosciences, Inc. and Teleost Biopharmaceuticals, LLC have decided to end their Licensing Agreement from early 2023. This agreement allowed Klotho to develop and market certain drug patents and know-how from Teleost. Klotho chose to terminate this agreement as these rights no longer align with their business focus and research objectives.
For a thorough assessment of KLTO stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Class Action Lawsuit Against Domino’s Pizza, Inc. (NYSE:DPZ)
- 3 Penny Stocks to Watch Now, 11/24/24
- Palantir Stock Keeps Hitting New 52-Week Highs. Is it Still a Buy?
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
